Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Neurol ; 24(1): 183, 2024 May 31.
Article in English | MEDLINE | ID: mdl-38822243

ABSTRACT

BACKGROUND: Serum uric acid (UA) and the neutrophil-to-lymphocyte ratio (NLR) have been reported to be associated with outcomes in acute ischemic stroke (AIS). However, whether UA is related to the prognosis of AIS patients undergoing intravenous thrombolysis (IVT) remains inconclusive. We sought to explore the combined effect of UA and NLR on the prognosis of AIS treated with IVT. METHODS: A total of 555 AIS patients receiving IVT treatment were enrolled. Patients were categorized into four groups according to the levels of UA and NLR: LNNU (low NLR and normal UA), LNHU (low NLR and high UA), HNNU (high NLR and normal UA), and HNHU (high NLR and high UA). Multivariable logistic regression analysis was used to evaluate the value of serum UA level and NLR in predicting prognosis. The primary outcomes were major disability (modified Rankin scale (mRS) score 3-5) and death within 3 months. RESULTS: After multivariate adjustment, a high NLR (≥ 3.94) increased the risk of 3-month death or major disability (OR, 2.23; 95% CI, 1.42 to 3.55, p < 0.001). However, there was no statistically significant association between a high UA level (≥ 313.00 µmol/L) and clinical outcome. HNHU was associated with a 5.09-fold increase in the risk of death (OR, 5.09; 95% CI, 1.31-19.83; P value = 0.019) and a 1.98-fold increase in the risk of major disability (OR, 1.98; 95% CI 1.07-3.68; P value = 0.030) in comparison to LNNU. CONCLUSIONS: High serum UA levels combined with high NLR were independently associated with 3-month death and major disability in AIS patients after IVT.


Subject(s)
Ischemic Stroke , Lymphocytes , Neutrophils , Thrombolytic Therapy , Uric Acid , Humans , Uric Acid/blood , Female , Male , Ischemic Stroke/blood , Ischemic Stroke/drug therapy , Ischemic Stroke/diagnosis , Ischemic Stroke/mortality , Aged , Middle Aged , Thrombolytic Therapy/methods , Prognosis , Retrospective Studies , Aged, 80 and over , Administration, Intravenous , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use
2.
Brain Res Bull ; 177: 363-372, 2021 12.
Article in English | MEDLINE | ID: mdl-34699917

ABSTRACT

Depression is one of the strongest predictors of quality of life in patients with Parkinson's disease (PD). Despite the high prevalence of depression, there is no clear guidance for its treatment in PD because the evidence for the efficacy of most antidepressants remains insufficient. Pramipexole, a dopamine agonist, is one of the few drugs that has proven to be clinically useful. However, the underlying mechanisms of antidepressive effects of pramipexole are still unknown. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model, dopamine D2 receptor (DRD2) and D3 receptor (DRD3) knockout mice were used in our study. Compared with other dopamine D2-like receptor agonists and madopar, pramipexole improved depression-like behavior and alleviate bradykinesia in an MPTP-induced mouse model of PD. Pramipexole significantly improved depression-like behavior in DRD2-/- mice but not in DRD3-/- mice. These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2. Our findings highlight the need to develop novel dopamine agonists specifically targeting DRD3 for the treatment of depression in PD in the future.


Subject(s)
Parkinson Disease , Receptors, Dopamine D3 , Animals , Benzothiazoles/pharmacology , Depression/drug therapy , Dopamine Agonists/pharmacology , Humans , Mice , Mice, Knockout , Parkinson Disease/drug therapy , Pramipexole/pharmacology , Pramipexole/therapeutic use , Quality of Life
3.
Medicine (Baltimore) ; 100(25): e26448, 2021 Jun 25.
Article in English | MEDLINE | ID: mdl-34160439

ABSTRACT

INTRODUCTION: Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is an increasingly recognized type of steroid-responsive autoimmune disease of the nervous system. Defined in 2016, it is associated with the presence of anti-GFAP immunoglobulinG in the serum or cerebrospinal fluid (CSF) of affected patients. PATIENT CHARACTERISTICS: Herein, we report a case of acute neurological symptoms, including headache, fever, confusion, and paralysis of the lower extremities. CSF analysis revealed lymphocytic pleocytosis and elevated protein levels, indicating acute disseminated encephalomyelitis, and the patient was given immunotherapy. Cranial magnetic resonance imaging showed multifocal T2/fluid-attenuated inversion recovery hyperintense signal changes in the periventricular white matter, and electromyography testing showed changes consistent with severe sensorimotor neuropathy, indicating the involvement of the brain and peripheral nerves. DIAGNOSES: Finally, a diagnosis of autoimmune GFAP astrocytopathy was confirmed due to the presence of GFAP-immunoglobulinG in the patient's CSF. INTERVENTIONS: The patient was treated with one course of intravenous immunoglobulin therapy, then followed with intravenous methylprednisolone (1.0 g/d for 3 days) and oral prednisolone. OUTCOMES: At 1 week after intravenous immunoglobulin therapy, his level of consciousness improved. However, flaccid paralysis persisted without substantial improvement. CONCLUSION: In conclusion, the provision of an accurate early diagnosis and appropriate treatment are crucial for improving the prognosis of patients with autoimmune GFAP astrocytopathy. Further, this case highlights the importance of recognizing the role of peripheral nerve involvement in GFAP autoimmunity.


Subject(s)
Autoantibodies/cerebrospinal fluid , Encephalomyelitis, Acute Disseminated/diagnosis , Glial Fibrillary Acidic Protein/immunology , Polyneuropathies/diagnosis , White Matter/immunology , Astrocytes/immunology , Astrocytes/pathology , Autoantibodies/immunology , Diagnosis, Differential , Humans , Immunoglobulins, Intravenous/administration & dosage , Magnetic Resonance Imaging , Male , Middle Aged , Polyneuropathies/cerebrospinal fluid , Polyneuropathies/drug therapy , Polyneuropathies/immunology , Treatment Outcome , White Matter/cytology , White Matter/diagnostic imaging
4.
Ecotoxicol Environ Saf ; 202: 110914, 2020 Oct 01.
Article in English | MEDLINE | ID: mdl-32800249

ABSTRACT

Bombyx mori(Linnaeus, 1758) is an important economical insect, and the sericulture is a flourishing industry in many developing countries. Pyriproxyfen, a juvenile hormone pesticide, is often applied to cultivations widely in the world, and its exposure often resulted in silk yield reduction and non-cocooning. However, the effect of pyriproxyfen exposure on cocooning and gene expression level in the silk gland of B. mori has not been studied yet, and this study focused on the above issues. The result indicated that pyriproxyfen exposure can lead to silk gland injury, reduction of silk yield and cocooning rate. Furthermore, the expression levels of silk protein synthesis related genes were down regulated significantly. The same change trends were shown between PI3K/Akt and CncC/Keap1 pathway, which is the expressions of key genes can be elevated by pyriproxyfen exposure. In addition, the activity of detoxification enzymes (P450, GST and CarE) and the expression levels of detoxification genes were elevated after pyriproxyfen exposure, suggesting that detoxification enzymes may play an important role in detoxification of pyriproxyfen in silk gland. These results provided possible clues to the silk gland injury and gene transcriptional level changes in silkworm after pyriproxyfen exposure.


Subject(s)
Bombyx/physiology , Insecticides/toxicity , Pyridines/toxicity , Animals , Bombyx/drug effects , Bombyx/genetics , Down-Regulation , Insect Proteins/genetics , Kelch-Like ECH-Associated Protein 1/genetics , Larva/metabolism , NF-E2-Related Factor 2/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Protein Biosynthesis , Silk/biosynthesis , Silk/genetics , Silk/metabolism
5.
Neurobiol Aging ; 60: 104-115, 2017 12.
Article in English | MEDLINE | ID: mdl-28941726

ABSTRACT

Many studies reveal that BAG3 plays a critical role in the regulation of protein degradation via macroautophagy. However, it remains unknown whether BAG3 affects the quality control of α-synuclein (SNCA), a Parkinson's disease-related protein. In this study, we demonstrated the increases of BAG3 expression in the ventral midbrain of SNCAA53T transgenic mice and also in MG132-treated PC12 cells overexpressing wild-type SNCA (SNCAWT-PC12). Moreover, we showed that BAG3 overexpression was sufficient to enhance the autophagy activity while knockdown of Bag3 reduced it in SNCAWT-PC12 cells. Immunoprecipitation revealed that BAG3 interacted with heat shock protein 70 and sequestosome 1. The immunostaining also showed the perinuclear accumulation and colocalization of BAG3 with these 2 proteins, as well as with LC3 dots in tyrosine hydroxylase-positive neurons in the midbrain of SNCAA53T mice. BAG3 overexpression was able to modulate SNCA degradation via macroautophagy which was prevented by Atg5 knockdown. Taken together, these results indicate that BAG3 plays a relevant role in regulating SNCA clearance via macroautophagy, and the heat shock protein 70-BAG3-sequestosome 1 complex may be involved in this process.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Apoptosis Regulatory Proteins/physiology , Autophagy/genetics , Autophagy/physiology , alpha-Synuclein/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Animals , Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Gene Expression , HSP70 Heat-Shock Proteins/physiology , Male , Mesencephalon/metabolism , Mice, Transgenic , PC12 Cells , Rats , Sequestosome-1 Protein/physiology
6.
Mol Pain ; 13: 1744806917691525, 2017 01.
Article in English | MEDLINE | ID: mdl-28326933

ABSTRACT

Background Although pain is one of the most distressing non-motor symptoms among patients with Parkinson's disease, the underlying mechanisms of pain in Parkinson's disease remain elusive. The aim of the present study was to investigate the role of serotonin (5-hydroxytryptamine) in the rostral ventromedial medulla (RVM) and spinal cord in pain sensory abnormalities in a 6-hydroxydopamine-treated rat model of Parkinson's disease. Methods The rotarod test was used to evaluate motor function. The radiant heat test and von Frey test were conducted to evaluate thermal and mechanical pain thresholds, respectively. Immunofluorescence was used to examine 5-hydroxytryptamine neurons and fibers in the rostral ventromedial medulla and spinal cord. High-performance liquid chromatography was used to determine 5-hydroxytryptamine and 5-hydroxyindoleacetic acid levels. Results The duration of running time on the rotarod test was significantly reduced in 6-hydroxydopamine-treated rats. Nociceptive thresholds of both mechanical and heat pain were reduced compared to sham-treated rats. In addition to the degeneration of cell bodies and fibers in the substantia nigra pars compacta, the number of rostral ventromedial medulla 5-hydroxytryptamine neurons and 5-hydroxytryptamine fibers in the spinal dorsal horn was dramatically decreased. 5-Hydroxytryptamine concentrations in both the rostral ventromedial medulla and spinal cord were reduced. Furthermore, the administration of citalopram significantly attenuated pain hypersensitivity. Interestingly, Intra-rostral ventromedial medulla (intra-RVM) microinjection of 5,7-dihydroxytryptamine partially reversed pain hypersensitivity of 6-hydroxydopamine-treated rats. Conclusions These results suggest that the decreased 5-hydroxytryptamine contents in the rostral ventromedial medulla and spinal dorsal horn may be involved in hyperalgesia in the 6-hydroxydopamine-induced rat model of Parkinson's disease.


Subject(s)
Hyperalgesia/drug therapy , Hyperalgesia/etiology , Medulla Oblongata/metabolism , Parkinson Disease/complications , Serotonin/metabolism , Signal Transduction/physiology , Spinal Cord/metabolism , 5,7-Dihydroxytryptamine/therapeutic use , Animals , Disease Models, Animal , Indoles/metabolism , Male , Medulla Oblongata/drug effects , Oxidopamine/toxicity , Parkinson Disease/etiology , Parkinson Disease/pathology , Rats , Rats, Sprague-Dawley , Receptors, Opioid, mu/metabolism , Serotonin Agents/pharmacology , Selective Serotonin Reuptake Inhibitors/pharmacology , Spinal Cord/drug effects , Sympatholytics/toxicity , Tyrosine 3-Monooxygenase/metabolism , gamma-Aminobutyric Acid/metabolism
7.
Biochem Biophys Res Commun ; 455(3-4): 353-7, 2014 Dec 12.
Article in English | MEDLINE | ID: mdl-25446097

ABSTRACT

It has been demonstrated that acid sensing ionic channels (ASICs) are present in the central and peripheral nervous system of mammals, including the retina. However, it remains unclear whether the zebrafish retina also expresses ASICs. In the present study, the expression and distribution of zasic1 were examined in the retina of zebrafish. Both zasic1 mRNA and protein expressions were detected in the adult zebrafish retina. A wide distribution of ASIC1 in zebrafish retina was confirmed using whole mount in situ hybridization and immunohistochemistry study. Acidosis-induced currents in the isolated retinal ganglion cells (RGCs) were also recorded using whole cell patch clamping. Moreover, blockade of ASICs channel significantly reduced the locomotion of larval zebrafish in response to light exposure. In sum, our data demonstrate the presence of ASIC1 and its possible functional relevance in the retina of zebrafish.


Subject(s)
Acid Sensing Ion Channels/physiology , Retina/metabolism , Zebrafish Proteins/physiology , Zebrafish/genetics , Acid Sensing Ion Channels/genetics , Animals , Gene Expression Regulation, Developmental , Immunohistochemistry , In Situ Hybridization , Larva , Light , Microscopy, Fluorescence , Motor Activity , Patch-Clamp Techniques , RNA, Messenger/metabolism , Retinal Ganglion Cells/cytology , Zebrafish/physiology , Zebrafish Proteins/genetics
8.
Med Phys ; 41(8): 081911, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25086542

ABSTRACT

PURPOSE: This paper describes a low-dose method for reconstructing three-dimensional models of femur, using a standard shape model (SSM) and two conventional x-ray images. METHODS: The x-ray images were taken in two orthogonal directions. The x-ray source and sensor configurations were documented. An optimized algorithm was employed to align the x-ray image to the three-dimensional model. A method of direct correspondence building is proposed for linking two-dimensional images with three-dimensional projections of a SSM. The reconstruction method proposed in this paper is based on a SSM, which was adapted for x-ray images of individual bones. The adaption was executed by deforming the template bone shape until its silhouette boundary exactly matched the x-ray image of the individual bone. A silhouette-based unit free-form deformation method was evaluated for its suitability in the adaption of the SSM for x-ray images. Comprehensive experiments were designed and conducted for 35 specimens. RESULTS: The validity of the low-dose reconstruction method was demonstrated for the femur, with good results for accuracy (mean error of 1.1 mm, root-mean-square error of 2.1 mm), reproducibility (intraobservation coefficient of variation of 1.1%, interobservation coefficient of variation of 1.4%), and time consumption (mean of 5 min for a full femur). CONCLUSIONS: Once this approach has been validated in vivo, it should be suited to multiple applications of routine clinical and research practices.


Subject(s)
Femur/diagnostic imaging , Imaging, Three-Dimensional/methods , Adult , Algorithms , Humans , Male , Middle Aged , Radiation Dosage , Radiography , Reproducibility of Results , Time
SELECTION OF CITATIONS
SEARCH DETAIL
...